The initiative aims to invest in or acquire small antibiotic companies developing new drugs and therapies. Slated for a formal announcement July 9, the coalition will involve drugmakers such as Eli Lilly, Pfizer, Merck, Boehringer Ingelheim and Bayer.
The venture builds upon the work being done by CARB-X, a public-private partnership formed in 2016 to fund antibiotic development as patients’ need for innovative treatments continues to grow.
More articles on pharmacy:
Cheap steroid in shortage after being posited as potential COVID-19 treatment
Regeneron paid patient charity millions in kickbacks, lawsuit claims
Novartis pays DOJ, SEC $347M in kickback scheme settlement
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
